Abstract
Bevacizumab combination chemotherapy has been reported to extend progression-free survival, and is known to show a high response rate. We investigated the treatment results and safety of bevacizumab+paclitaxel therapy at our hospital. This study included 25 women with advanced/recurrent breast cancer. Mean age was 58 years. The breast cancer was luminal type in 13 cases, HER2 type in 5 cases, and triple-negative in 7 cases. The treatment was given as the first line or second line in 18 cases and the third line or later in 7 cases. Response rates were 62% for luminal type, 40% for HER2 type, 57% for triple-negative, 67% for the first/second line treatment, and 29% for the third line or later. All cases with clinical symptoms showed improvement of those symptoms. Grade 3 or higher adverse events comprised three cases of peripheral neuropathy, four cases of hypertension, and three cases of neutropenia. This treatment is relatively safe to implement, and potentially offers a higher response rate when introduced at the early stages of treatment. Rapid elimination of clinical symptoms is believed to contribute to improved quality of life (QOL).
